Innovating Works

COVIRNA

Financiado
A diagnostic test to improve surveillance and care of COVID 19 patients
Coronavirus disease 2019 (COVID-19) caused by infection with SARS coronavirus 2 (SARS-CoV-2) has reached pandemic proportions with more than 7 million people infected and 0.4 million people killed worldwide. Death rates are accent... Coronavirus disease 2019 (COVID-19) caused by infection with SARS coronavirus 2 (SARS-CoV-2) has reached pandemic proportions with more than 7 million people infected and 0.4 million people killed worldwide. Death rates are accentuated by cardiovascular comorbidities and arrhythmias leading to unexpected major cardiovascular events. Being able to identify COVID-19 patients at risk of developing cardiovascular events leading to death would allow improving surveillance and care. Currently, there is no accurate method to predict outcome of COVID-19 patients. COVIRNA is a patient-centered Innovation Action aiming to satisfy this urgent and unmet need. COVIRNA will complete and deploy a prognostic system based on cardiovascular biomarkers of COVID-19 clinical outcomes combined with digital tools and artificial intelligence analytics (i.e. prediction model). Complementary expertise of 15 EU partners from the healthcare sector, academia, association and industry will allow conducting a large retrospective study on existing cohorts of COVID-19 patients. By upscaling the already validated and patented research use only FIMICS panel of cardiac-enriched long noncoding RNA biomarkers into an in-vitro diagnostic test (COVIRNA) adapted to COVID-19 patients, the project will quickly deliver a minimally-invasive, simple yet robust and affordable prognosis tool that can be used in the context of the current COVID-19 crisis as well as in further major health issues. By tackling the cardiovascular complications in COVID-19, known to contribute significantly to mortality, the project outputs are expected to have a major impact on the pandemic outcomes. The COVIRNA test will be CE-marked and prepared for commercialization, allowing to risk stratify patients, adapt therapies and to inform drug design. ver más
30/04/2023
LIH
4M€
Duración del proyecto: 30 meses Fecha Inicio: 2020-10-13
Fecha Fin: 2023-04-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2023-04-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
SC1-PHE-CORONAVIRUS-2020-2B: Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL)
Cerrada hace 4 años
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
LUXEMBOURG INSTITUTE OF HEALTH No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5